Irawati K. Kandela, Ph.D. - Publications

2006 University of Wisconsin, Madison, Madison, WI 
Pharmacology, Immunology

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, Sagar V, Luan Y, Chalmers ZR, Unno K, Mok H, Vatapalli R, Yoo YA, Rodriguez Y, Kandela I, et al. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell. PMID 31679823 DOI: 10.1016/J.Ccell.2019.10.001  0.337
2018 Frankowski KJ, Wang C, Patnaik S, Schoenen FJ, Southall N, Li D, Teper Y, Sun W, Kandela I, Hu D, Dextras C, Knotts Z, Bian Y, Norton J, Titus S, et al. Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science Translational Medicine. 10. PMID 29769289 DOI: 10.1126/Scitranslmed.Aap8307  0.305
2018 Kamoun W, Swindell E, Pien C, Luus L, Cain J, Kandela I, Huang R, Tipparaju S, Kirpotin D, Bshara W, Askoxylakis V, Morrison C, Drummond D. Abstract 5771: Targeting EphA2 in bladder cancer using a novel antibody-directed nanotherapeutic Cancer Research. 78: 5771-5771. DOI: 10.1158/1538-7445.Am2018-5771  0.363
2017 Liu Y, Lou G, Norton JT, Wang C, Kandela I, Tang S, Shank NI, Gupta P, Huang M, Avram MJ, Green R, Mazar A, Appella D, Chen Z, Huang S. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28821631 DOI: 10.1096/Fj.201700306Rr  0.301
2017 Kandela IK, McAuliffe KJ, Cochran LE, Barrett AGM, Hoffman BM, Mazar AP, Trivedi ER. Discovery of the Antitumor Effects of a Porphyrazine Diol (Pz 285) in MDA-MB-231 Breast Tumor Xenograft Models in Mice. Acs Medicinal Chemistry Letters. 8: 705-709. PMID 28740602 DOI: 10.1021/Acsmedchemlett.7B00063  0.322
2017 Aird F, Kandela I, Mantis C. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Elife. 6. PMID 28100400 DOI: 10.7554/Elife.21253  0.306
2017 Kandela I, Aird F. Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data. Elife. 6. PMID 28100397 DOI: 10.7554/Elife.17044  0.303
2017 Mantis C, Kandela I, Aird F. Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Elife. 6. PMID 28100395 DOI: 10.7554/Elife.17584  0.316
2016 Hendrix MJ, Kandela I, Mazar AP, Seftor EA, Seftor RE, Margaryan NV, Strizzi L, Murphy GF, Long GV, Scolyer RA. Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 27775691 DOI: 10.1038/Labinvest.2016.107  0.337
2016 Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, Kritharis A, Kandela I, Hlatky L, Sitkovsky MV, Mazar AP, Gartenhaus RB, Evens AM. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC Dependent Cell Death in T-Cell and Hodgkin Lymphoma. Cancer Research. PMID 26988986 DOI: 10.1158/0008-5472.Can-15-2477  0.32
2016 Mantis C, Kandela I, Aird F. Author response: Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Elife. DOI: 10.7554/Elife.17584.012  0.305
2015 Kandela I, Chou J, Chow K. Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Elife. 4. PMID 27879198 DOI: 10.7554/Elife.06959  0.329
2015 Kandela I, Jin HY, Owen K. Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Elife. 4. PMID 26111384 DOI: 10.7554/Elife.07072  0.306
2015 Kandela I, Chou J, Chow K. Correction: Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Elife. 4. PMID 26052861 DOI: 10.7554/Elife.09169  0.307
2015 Swanson KI, Clark PA, Zhang RR, Kandela IK, Farhoud M, Weichert JP, Kuo JS. Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection. Neurosurgery. 76: 115-23; discussion 1. PMID 25549194 DOI: 10.1227/Neu.0000000000000622  0.348
2015 Dam DH, Culver KS, Kandela I, Lee RC, Chandra K, Lee H, Mantis C, Ugolkov A, Mazar AP, Odom TW. Biodistribution and in vivo toxicity of aptamer-loaded gold nanostars. Nanomedicine : Nanotechnology, Biology, and Medicine. 11: 671-9. PMID 25461281 DOI: 10.1016/J.Nano.2014.10.005  0.333
2015 Kandela I, Chou J, Chow K. Author response: Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Elife. DOI: 10.7554/Elife.06959.003  0.305
2015 Wang C, Frankowski K, Yaroslav T, Patnaik S, Schoenen F, Southall N, Sun W, Titus S, Griner L, Dextras C, Sultan J, Kandela I, Lewandowska M, Wen Y, Norton J, et al. Abstract 5368: Metarrestin effectively disassembles PNCs and inhibits metastasis Cancer Research. 75: 5368-5368. DOI: 10.1158/1538-7445.Am2015-5368  0.327
2014 Ravi D, Bhalla S, Gartenhaus RB, Crombie J, Kandela I, Sharma J, Mazar A, Evens AM. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6023-33. PMID 25316819 DOI: 10.1158/1078-0432.Ccr-14-1532  0.314
2014 Weichert JP, Clark PA, Kandela IK, Vaccaro AM, Clarke W, Longino MA, Pinchuk AN, Farhoud M, Swanson KI, Floberg JM, Grudzinski J, Titz B, Traynor AM, Chen HE, Hall LT, et al. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Science Translational Medicine. 6: 240ra75. PMID 24920661 DOI: 10.1126/Scitranslmed.3007646  0.326
2014 Dashnamoorthy R, Behesti A, Abermil N, Sharma J, Coyle M, Kandela I, Mazar A, Hlatky L, Evens AM. Genome-Wide Analysis Reveals MYC-Dependent Cell Death and Identifies Predictive Biomarkers of Ixazomib Sensitivity in Preclinical Models of T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Blood. 124: 3120-3120. DOI: 10.1182/Blood.V124.21.3120.3120  0.329
2014 Kuo JS, Weichert JP, Clark PA, Kandela IK, Vacaro A, Clark W, Longino M, Pinchuk A, Farhoud M, Swanson KI, Floberg J, Traynor A, Hall LT, Pazoles C. NOVEL ALKYLPHOSPHOCHOLINE ANALOGS FOR BROAD SPECTRUM CANCER IMAGING AND THERAPY Neuro-Oncology. 16: iii10-iii11. DOI: 10.1093/Neuonc/Nou206.37  0.363
2013 Dashnamoorthy R, Kandela I, Bhalla S, Mazar A. Evaluation Of Potency and The Associated Biology Of The Investigational Proteasome Inhibitor, Ixazomib: Redox, Autophagic, and MAPK-Dependent Cell Death In T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and Human Lymphoma Xenograft Models Blood. 122: 4407-4407. DOI: 10.1182/Blood.V122.21.4407.4407  0.328
2013 Kandela I, Ugolkov A, Francia G, Rabbani S, Kerbel RS, Mazar AP. Abstract 863: Inhibition of breast cancer metastaticprogression by a novel uPAR targeted monoclonal antibody, ATN-658, correlateswith the uPAR expression. Cancer Research. 73: 863-863. DOI: 10.1158/1538-7445.Am2013-863  0.352
2012 Dashnamoorthy R, Kandela I, Bhalla S, Galloway J, Zaretsky I, Mazar A, Evens AM. The 2nd Generation Proteasome Inhibitor, MLN2238: Potent Induction of Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and in Two Human Lymphoma Xenograft Models. Blood. 120: 2767-2767. DOI: 10.1182/Blood.V120.21.2767.2767  0.334
2012 Dashnamoorthy R, Bhalla S, Crombie J, Kandela I, Mazar A, Evens AM. Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor Blood. 120: 1646-1646. DOI: 10.1182/Blood.V120.21.1646.1646  0.323
2012 Pazoles C, Vaccaro A, Kandela I, Pinchuk A, Farhoud M, Longino M, Weichert J. Abstract 5740:124I-CLR1404 and131I-CLR1404: Broad spectrum diapeutic agents for cancer cell-targeted PET imaging and molecular radiotherapy Cancer Research. 72: 5740-5740. DOI: 10.1158/1538-7445.Am2012-5740  0.361
2012 Pazoles C, Vaccaro A, Kandela I, Pinchuk A, Farhoud M, Longino M, Weichert J. Abstract 3831: 131I-CLR1404 and CLR1404: Broad spectrum, cancer-targeted molecular radio- and chemotherapeutic phospholipid ether analogs Cancer Research. 72: 3831-3831. DOI: 10.1158/1538-7445.Am2012-3831  0.359
2012 Clark PA, Chen H, Mohamed M, Kandela IK, Longino MA, Pinchuk A, Weichert JP, Kuo JS. Abstract 3495: The novel phospholipid ether analog CLR1404 decreases glioblastoma stem cell proliferation, suppresses GBM growth, and improves survival Cancer Research. 72: 3495-3495. DOI: 10.1158/1538-7445.Am2012-3495  0.345
2008 Bleher R, Kandela I, Meyer DA, Albrecht RM. Immuno-EM using colloidal metal nanoparticles and electron spectroscopic imaging for co-localization at high spatial resolution. Journal of Microscopy. 230: 388-95. PMID 18503664 DOI: 10.1111/J.1365-2818.2008.01997.X  0.591
2008 Kandela IK, Bleher R, Albrecht RM. Immunolabeling for correlative light and electron microscopy on ultrathin cryosections. Microscopy and Microanalysis : the Official Journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada. 14: 159-65. PMID 18312726 DOI: 10.1017/S1431927608080239  0.593
2007 Kandela IK, Bleher R, Albrecht RM. Multiple correlative immunolabeling for light and electron microscopy using fluorophores and colloidal metal particles. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 55: 983-90. PMID 17652267 DOI: 10.1369/Jhc.6A7124.2007  0.609
2007 Kandela IK, Albrecht RM. Fluorescence quenching by colloidal heavy metals nanoparticles: implications for correlative fluorescence and electron microscopy studies. Scanning. 29: 152-61. PMID 17477396 DOI: 10.1002/Sca.20055  0.59
2007 Kaiser M, Heintz J, Kandela I, Albrecht R. Tumor Cell Death Induced by Membrane Melting via Immunotargeted, Inductively Heated Core/Shell Nanoparticles Microscopy and Microanalysis. 13. DOI: 10.1017/S1431927607073795  0.545
2006 Meyer DA, Bleher R, Kandela IK, Oliver JA, Albrecht RM. The development of alternative markers for transmission electron microscopy and correlative transmission electon and light microscopies Microscopy and Microanalysis. 12: 32-33. DOI: 10.1017/S1431927606069121  0.562
2004 Kandela IK, Bleher R, Albrecht RM. Correlative Labeling Studies in Light and Electron Microscopy Microscopy and Microanalysis. 10: 1212-1213. DOI: 10.1017/S1431927604884393  0.574
2003 Kandela I, Meyer D, Oshel P, Rosa-Molinar E, Albrecht RM. Fluorescence Quenching by Colloidal Heavy Metals: Implications for Correlative Fluorescence and Electron Microscopy Studies Microscopy and Microanalysis. 9: 1194-1195. DOI: 10.1017/S1431927603445972  0.581
2002 Kandela IK, Bartlett JA, Indig GL. Effect of molecular structure on the selective phototoxicity of triarylmethane dyes towards tumor cells. Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society For Photobiology. 1: 309-14. PMID 12653467 DOI: 10.1039/B110572H  0.331
Show low-probability matches.